drugset / Trial / NCT03454035
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1
Recruiting
45 enrolled
UNC Lineberger Comprehensive Cancer Center
BioMed Valley Discoveries, Inc · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
Timeline
- Start
- 2018-01-30
- Primary completion
- 2026-07-15
- Completion
- 2026-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Ulixertinib | Small molecule | 300 mg | Oral |